CalciMedica, Inc., a clinical-stage biotechnology company headquartered in La Jolla, California, is focused on creating treatments for life-threatening inflammatory diseases that currently ...
CalciMedica, Inc. is a clinical-stage biopharmaceutical company headquartered in La Jolla, California, dedicated to developing innovative therapies for life-threatening inflammatory diseases that currently lack adequate treatment options. The company's proprietary platform targets calcium release-activated calcium (CRAC) channels, which play a pivotal role in immune cell activation and inflammatory responses. By ...CalciMedica, Inc. is a clinical-stage biopharmaceutical company headquartered in La Jolla, California, dedicated to developing innovative therapies for life-threatening inflammatory diseases that currently lack adequate treatment options. The company's proprietary platform targets calcium release-activated calcium (CRAC) channels, which play a pivotal role in immune cell activation and inflammatory responses. By inhibiting these channels, CalciMedica aims to modulate the immune system and protect against cellular and tissue damage in severe conditions. The lead drug candidate, Auxora, is an intravenously administered, proprietary CRAC channel inhibitor currently in clinical development for acute pancreatitis, including its asparaginase-associated form, and acute kidney injury. These indications represent significant unmet medical needs with limited therapeutic options. The company also explores applications in other inflammatory and immunologic diseases. On the business side, CalciMedica went public in June 2023 and is listed on the NASDAQ Capital Market under the ticker CALC. The company has a market capitalization of approximately $9.76 million as of the latest data, with a negative enterprise value, reflecting its pre-revenue stage. Financially, CalciMedica has no revenue, and its operating expenses are primarily directed towards research and development and general administrative activities. The company had 16 full-time employees as of the most recent report, emphasizing a lean operational structure typical of early-stage biotech firms. Key leadership includes CEO A. Rachel Leheny, who has over 30 years of life sciences experience, along with co-founder and Chief Scientific Officer Kenneth Stauderman. The executive team brings extensive expertise in drug development and corporate strategy. CalciMedica's future prospects hinge on the successful advancement of Auxora through clinical trials and potential regulatory approval, which could address critical needs in acute inflammatory conditions. The company's commitment to CRAC channel inhibition as a novel mechanism offers a differentiated approach in the biotechnology landscape, with the potential to improve patient outcomes in devastating diseases.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$0
—
—
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-29.6M
-115.8%
-253.8%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
—
—
—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
—
—
—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
—
—
—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-21.2M
-0.2%
+4.9%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
—
—
—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
-146.1%
—
—
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
3.58x
-33.0%
+246.3%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
